Nexentis Technologies Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you understand how Nexentis Technologies performed this year. My goal is to translate complex filings into plain English so you can decide if this company belongs in your portfolio.

1. What does this company do?

Nexentis has shifted away from food safety to focus on two high-stakes, speculative bets:

• MitoCareX (Biotech): They use AI to find cancer drugs that target specific proteins in lung cancer cells. They focus on early-stage discovery, aiming to disrupt how tumor cells function.
• Solterra (Energy): They act as "project developers" for solar energy in Italy, Poland, and Germany. They find land, secure grid connections, and handle government permits. They aim to sell these "Ready-to-Build" projects to large energy companies.

2. The Biotech "Moonshot"

MitoCareX is the core of their biotech strategy, powered by an AI platform called MITOLINE™.

• The Reality Check: In February 2025, they withdrew their patent applications because their scientific results did not support their claims. This setback pushed their research timeline back by 18 months. Furthermore, they have no sales team. If they ever get a drug approved, they would need to raise $150 million to $200 million to build a commercial team or partner with a larger pharmaceutical company.

3. The Solar Strategy: A "Flipping" Business

Solterra operates in a crowded market, competing against both global giants and small, local firms.

• The Process: They navigate complex permitting processes that take 18 to 36 months. By the end of 2025, they had 450 megawatts of solar capacity in development.
• The Reality: Their market share in Europe is tiny, representing less than 0.1% of the regional market. Success depends entirely on navigating local rules and selling projects at a target profit margin of 15% to 20%.

4. Financial Health: The "Going Concern" Warning

This is the most critical part for any investor: The company is in serious financial trouble.

• The Numbers: By December 31, 2025, the company had lost $38.5 million. Revenue for the year was just $120,000, while operating expenses hit $8.2 million.
• The Warning: Auditors have expressed "substantial doubt" about the company’s ability to stay in business. They hold only $1.4 million in cash, which will not cover operations past the second quarter of 2026.
• Dilution: They fund operations by selling more shares, which reduces your ownership percentage. They issued 4.2 million new shares in 2025 and executed a 1-for-35 reverse stock split in September 2025 to keep their share price above the $1.00 Nasdaq requirement.
• Lean Team: With only nine employees, they are running on a skeleton crew, which limits their ability to manage complex international projects.

5. Future Outlook & Risks

Nexentis is a high-risk venture. They burn about $650,000 in cash every month, have almost no revenue, and face a "going concern" warning. Between the failed patents and the long, uncertain solar timelines, the path to profit is unclear. The company must raise at least $10 million within the next year to survive, which will likely mean issuing more shares and further shrinking your stake.

Investor Takeaway: When looking at a company with a "going concern" warning, a high cash burn rate, and a history of share dilution, it is important to weigh the potential of their AI and solar projects against the very real possibility that the company may run out of capital before those projects reach profitability. Proceed with extreme caution.